Comparison of 68Ga-DOTA-Tyr3-octreotide and 18F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 1, 2010, Pages 68-75

  Putzer, D ^a   Gabriel, M ^a   Kendler, D ^a   Henninger, B ^a   Knoflach, M ^a   Kroiss, A ^a   Vonguggenberg, E ^a   Warwitz, B ^a   Virgolini, I J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Fluorodopa F 18; Neuroendocrine tumors; Octreotide, DOTA Tyr(3); Positron emission tomography

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE GA 68; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYPHENYLALANINE F 18; RADIOISOTOPE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EXPERIENCE; FEMALE; FOLLOW UP; GOLD STANDARD; HISTOLOGY; HUMAN; HUMAN TISSUE; INFORMATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; TUMOR DIAGNOSIS;

ADOLESCENT; ADULT; AGED; DIHYDROXYPHENYLALANINE; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY; YOUNG ADULT;

EID: 77952519078     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-551
2. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
3. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704-1713
4. Virgolini IJ, Traub T, Novotny C, Leimer M, Füger B, Li SR et al. New trends in peptide receptor radioligands. QJ Nucl Med 2001;45:153-59.
5. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79-83.
6. Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Rusniewski P et al. Impact of 18F-DOPA PET on Management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab 2009;94:1295-1301
7. Hardy OT, Hernandez-Pampaloni M, Saffer JR, Scheuermann JS, Ernst LM, Freifelder R et al. Accuracy of 18F-Fluorodopa PET for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrin Metab 2007;92:4706-4711
8. Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A et al. A fully automated synthesis for die preparation of 68Ga-labelled peptides. Nucl Med Commun 2007;28:870-875 (Pubitemid 47494113)
9. Luxen A, Perlmutter M, Bida GT, Van Moffaert G, Cook JS, Satyamurthy N et al. Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. Int J Rad Appl Instrum A 1990;41:275-281
10. Even-Sapir. PET/CT in malignant bone disease. Sem Musc Rad 2007;11:312-321
11. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTA-TOC: preliminary data. Eur J Nucl Med 2001;28:1751-1757
12. Debray MP, Geoffroy O, Laissy JP, Lebtahi R, Silbermann-Hoffmann O, Henry-Feugeas MC et al. Imaging appearance of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 2001;74:1065-70.
13. Ambrosini V, Marzola MC, Rubello D, Fanti S; 68Ga-somatostatin analogues PET and 18F-DOPA PET in medullary thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37:46-48
14. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1431-1438
15. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H et al. Whole-body 18F DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;8:373-380 (Pubitemid 32667172)
16. Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 2003;30:689-694 (Pubitemid 36612951)
17. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I et al. Pheochromocytomas: Detection with 18F-DOPA Whole-Body PET - Initial Results. Radiology 2002;222:507-512
18. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64-71. (Pubitemid 32120808)
19. Hoegerle S, Schneider B, Kraft A, Moser E, Nitzsche EU. Imaging of a metastatic gastrointestinal carcinoid by F-18-DOPA positron emission tomography. Nuklearmedizin 1999;38:127-130 (Pubitemid 29287732)
20. Becherer A, Szabó M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 2004;45:1161-1167
21. Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours; Eur J Nucl Med Mol Imaging 2009.36:765-70.
22. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmanns KP, Guelechyn KY; 6-L-18-fluorodihydrxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. JNM 2008;49:573-586
23. Groves AM, Win T, Haim SB, Ell PJ. Non-[18F]FDG PET in clinical oncology. Lancet Oncol 2007;8:822-830
24. Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol 2009;19:1425-1434
25. Sundin A, Garske U, Orlefors H; Nuclear imaging of neuroendorine tumours. Best Pract Res Clin Endonrinol Metab 2007;21:69-85.
26. Nanni C, Fanti S, Rubello D; 18F-DOPA PET and PET/CT. JNM 2007; 1577-1578
27. Koopmans KP, deVries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006;7:728-734
28. Kauhanen S, Seppanen M, Minn H, Gullichsen R, Salonen A, Alanen K et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or ,-cell hyperplasia in adult patients. J Clin Endocrinol Metab 2007;92:1237-1244
29. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-DOPA and 11C-5-HTP PET. J Clin Oncol 2008;26:5307-8; author reply 5308-5309
30. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991;64:576-673